Autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC) are two very closely related autoimmune liver diseases with overlapping clinical features and similar management strategies. The purpose of this study was to assess the utility of quantitative imaging markers to distinguish ASC from AIH in paediatrics. 66 participants (N = 52 AIH, N = 14 ASC) aged 14.4 ± 3.3 years scheduled to undergo routine biopsy and baseline serum liver biochemistry testing were invited to undergo MRI (non-contrast abdominal MRI and 3D fast spin-echo MRCP). Multiparametric MRI was used to measure fibro-inflammation with corrected T1 (cT1), while the biliary tree was modelled using quantitative MRCP (MRCP +). Mann–Whitney U tests were performed to compare liver function tests with imaging markers between patient groups (ASC vs AIH). Receiver operating characteristic curves and stepwise logistic regressions were used to identify the best combination of markers to discriminate between ASC and AIH. Correlations between liver function tests and imaging markers were performed using Spearman’s rank correlation. cT1 was significantly correlated with liver function tests (range 0.33 ≤ R ≤ 56, p < 0.05), as well as with fibrosis, lobular and portal inflammation (range 0.31 ≤ R ≤ 42, p < 0.05). 19 MRCP + metrics correlated significantly with liver function tests (range 0.29 ≤ R ≤ 0.43, p < 0.05). GGT and MRCP + metrics were significantly higher in ASC compared to those with AIH. The best multivariable model for distinguishing ASC from AIH included total number of ducts and the sum of relative severity of both strictures and dilatations AUC: 0.91 (95% CI 0.78–1). Quantitative MRCP metrics are a good discriminator of ASC from AIH.
Non-alcoholic fatty liver disease (NAFLD), a disorder characterised by pathological accumulation of non-visible free fatty acids and visible triglyceride in hepatocytes, is on the rise globally in both adult and paediatric populations.1 Evidence suggests that 20%–50% of the European Union and US populations exhibit features of NAFLD,2 driven by higher rates of obesity, insulin resistance and type 2 diabetes, and metabolic syndrome.3 Additionally, recognition of a growing number of patients with ‘lean NAFLD’ who are not obese, but have high levels of visceral fat, diets high in fats and carbohydrates, or who have genetic risk factors, has increased.4 Of patients with NAFLD, 6%–55% will have histological signs of non-alcoholic steatohepatitis (NASH), which if left unmanaged can lead to cirrhosis and potentially hepatocellular carcinoma.5
Aims: Annotation of liver biopsies for disease staging is increasingly aided by digital pathology; however, existing systems do not quantify inflammation and steatosis within an anatomical framework. We hypothesise that an artificial intelligence (AI) system that quantifies portal tracts (PT) and the anatomical distribution of steatotic vesicles and inflammatory cells will align with manual pathologist scoring and stratify liver diseases. Methods: In this observational, cross-sectional study, digitised images of haematoxylin and eosin-stained specimens were pooled from four independent cohorts of metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis (MASH) or autoimmune hepatitis (AIH) (n=390: 89 MASLD, 238 MASH, 63 AIH). PT, steatosis, and inflammation were quantified using a proprietary AI system and scored by expert pathologists. Results: The percentage of steatosis was higher in MASH (7.5%) than in MASLD (3.2%). Lobular regions had larger steatotic vesicles (260 vs 190 μm 2 ). AI-derived steatosis quantification correlated with manual grading (r s =0.72). The inflammatory cell number (ICN) was twofold higher in AIH than MASLD/MASH in interface (390 vs 140), portal (4600 vs 1500) and lobular (1500 vs 650) regions. Portal inflammation from manual grading correlated with ICN count at PT (r s =0.71) but not lobular regions (r s ≤0.29). For equivalent grades of portal inflammation, the ICN was up to threefold higher in AIH than in MASLD/MASH (r s =0.71). Conclusion: A new AI system for anatomical quantification of liver biopsy features measured variation in fat and inflammation across the lobule. It showed that inflammation burden was higher in AIH than MASLD/MASH, despite equivalent portal grades, providing objective support for histological scoring.
Background & Aims: Annotation of liver biopsies, for disease staging is increasingly aided by digital pathology, however existing systems do not quantify inflammation and steatosis within an anatomical framework. We developed an AI system to quantify portal tracts (PT) and disease features and their regional distribution in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Autoimmune Hepatitis (AIH). Methods: Digitised images of haematoxylin and eosin-stained specimens were pooled from 4 clinical cohorts (n=390: 89 MASLD, 238 MASH, 63 AIH). Portal tracts, regional steatosis, interface hepatitis, portal and lobular inflammation were quantified using a proprietary AI system and scored by expert pathologists. Results: The percentage of steatosis was higher in MASH (7.5%) compared to MASLD (3.2%, p<0.0001). Lobular regions had larger steatotic vesicles (260 vs 190mm 2 , p<0.0001). AI-derived steatosis quantification correlated with manual grading (r s =0.72; p<0.0001). The inflammatory cell number (ICN) was 2-fold higher in AIH compared to MASLD/MASH in interface [390 vs 140; p<0.0001], portal [4600 vs 1500], and lobular [1500 vs 650] regions. Severity of portal inflammation from manual grading correlated well with ICN count at PT (r s =0.71; p<0.0001) but not lobular regions (r s =<0.1). For equivalent grades of portal inflammation, the ICN was up to 3-fold higher in AIH than in MASLD/MASH (r s =0.71; p<0.0001). Conclusion: Despite equivalent pathologist portal inflammation grades, the digital burden of inflammation was significantly higher in AIH than MASLD/MASH. This digital system quantifies PT, inflammation, and steatosis, providing powerful decision support for pathologists in AIH diagnosis and MASH staging. LAY SUMMARY: The detection of portal tracts is an important part of liver biopsy sample quality control and histological scoring. Using artificial intelligence, this study demonstrates a system that automatically detects and quantifies portal tracts and surrounding patterns of inflammation and steatosis. AI found that inflammation was in similar regions but was higher in autoimmune hepatitis than in metabolic dysfunction-associated steatohepatitis, despite similar grading from manual scoring. This AI system provides granular information that can aid biopsy grading and provide insights into liver disease progression and diagnosis.